Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary research objective of the project is to determine the role of eGC in microvascular reactivity in patients with coronary heart disease (CHD) before and after bypass grafting (cross-sectional study 2).The main objective of the project is to increase the excellence and interdisciplinarity of scientific work at MEFOS by connecting researchers from different scientific fields, improving conditions and resources for scientific work, and increasing international cooperation, in line with strategic objective 1: raising scientific excellence. The results of the project could provide pathophysiological insight into the development and maintenance of endothelial dysfunction in CVD, as well as identify new biomarkers for CVD.
The primary objective of this project is to determine the association between endothelial glycocalyx (eGC) and myocardial revascularization in patients undergoing coronary artery bypass grafting and clinical outcomes of treatment (observational prospective study 2).
Specific objective 2.1: Measure eGC thickness in coronary artery disease patients before and after surgery.
Specific objective 2.2: Determine the reactivity of the bypass graft sample in in vitro experiments.
Specific objective 2.3: Quantify soluble markers of eGC, oxidative stress, and inflammation from serum and PBMC samples, as well as antioxidant capacity.
Specific objective 2.4: Determine the association between the results of functional tests, eGC, and markers from specific objective 2.3 with clinical outcomes of treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Coronary Heart Disease (CHD) patients | Adult patients of both sexes over 18 years of age, undergoing elective coronary artery bypass grafting (CABG) and who provided written informed consent |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Endothelial glycocalyx | Measurement of the thickness of endothelial glycocalyx in coronary heart disease patients before and after bypass surgery - measured by Glycocheck | Perioperative/Periprocedural |
| Measure | Description | Time Frame |
|---|---|---|
| Bypass graft sample reactivity | Determine the reactivity of the bypass graft sample in in vitro experiments - measured by isolated vessel setup | Baseline, at one time point |
| Endothelial glycocalyx soluble markers |
| Measure | Description | Time Frame |
|---|---|---|
| Blood pressure | Automatic oscillometric measurement of systolic and diastolic blood measurement (mmHg) | Perioperative/Periprocedural |
| Heart rate | Automatic oscillometric measurement of heart rate (bpm) |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adult patients undergoing elective coronary artery bypass grafting (CABG)
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ines Drenjančević, MD, PhD | Contact | +385912241406 | ines.drenjancevic@mefos.hr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Osijek University Hospital | Recruiting | Osijek | 31000 | Croatia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003327 | Coronary Disease |
| D007249 | Inflammation |
| D003324 | Coronary Artery Disease |
| ID | Term |
|---|---|
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D014652 | Vascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
serum, plasma, peripheral blood mononuclear cells (PBMC)
Quantification of soluble markers of endothelial glycocalyx from serum or plasma samples in the specified groups - measured by ELISA assays (syndecan-1, syndecan-4, glypican-1, MMP-9)
| Perioperative/Periprocedural |
| Intracellular oxidative stress production | Quantification of intracellular oxidative stress production from peripheral blood mononuclear cells (PBMC) in the specified groups - measured by flow cytometry (DCF-DA and DHE) | Perioperative/Periprocedural |
| Inflammation | Quantification of inflammation from peripheral blood mononuclear cells (PBMC) in the specified groups - measured by Luminex assay (cytokine profile) and flow cytometry (macrophage frequency) | Perioperative/Periprocedural |
| Antioxidant capacity | Quantification of antioxidative enzyme concentration and activation from serum samples in the specified groups - measured by ELISA assays and UV-Vis spectrophotometry (SOD, GPx, CAT) | Perioperative/Periprocedural |
| Oxidative stress biomarkers | Quantification of oxidative stress biomarkers from serum samples in the specified groups - measured by ELISA assays (MPO, 8-iso prostaglandin F2a, OxLDL, AOPP) | Perioperative/Periprocedural |
| Perioperative/Periprocedural |
| Body Mass Index | Measurement of BMI (kg/m2) | Perioperative/Periprocedural |
| Body composition | Body composition and body fluid status measurement by a four-terminal portable impedance analyzer. Based on the value of skin resistance (Ohm) empirically derived formulas (the original manufacturer's software) will be used to calculate the estimated Fat Free Mass (FFM kg) and Fat (Fat Mass kg). | Perioperative/Periprocedural |
| Body fluid status | Body fluid status measurement by a four-terminal portable impedance analyzer. Based on the value of skin resistance (Ohm) empirically derived formulas (the original manufacturer's software) will be used to calculate the estimated Total Body Water (TBW L), Extracellular Water (ECW L), Intracellular Water (ICW L), Plasma Fluid (PF L) and Interstitial Fluid (IF L). | Perioperative/Periprocedural |
| D010335 |
| Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |